Release date:2016-06-06  Release:


Professor of Medicinal Chemistry

Director of Jiangsu Key Laboratory of

Drug Design and Optimization

School of Pharmacy

Phone: 86-25-83271351


Research Summary

Professor YOU’s research interesting is on the drug design and synthesis, the action mechanism of drug molecular and new drug research and development. The recent research focuced on two main fields: 1) natural product and its derivatives, structure-activities relationships, structure modification simplification and optimization; 2) Bioactive compound discovery for targeting on the protein structure and function, such as,  protein-protein interaction, protein degradation and the new drug design for cancer.


1989       Ph.D., Medicinal Chemistry, Shanghai Institute of Pharmaceutical Industry

1985       M.S.,  Medicinal Chemistry, Shanghai Institute of Pharmaceutical Industry

1982       B.S.,   Medicinal ChemistryNanjing College of Pharmacy (the former of China Pharmaceutical University)

Academic Experience

1994-      Professor of Medicinal Chemistry, China Pharmaceutical University, Associate Dean of School of Pharmacy (1995 to 2009), Dean of School of Pharmacy (2009 to 2015),

1994-1995  Senior Visiting Scholar, University of Strathclyde, UK

1990-1994 Associate Professor of Medicinal Chemistry, China Pharmaceutical University,

Awards and Honors

1994      Henry Fok outstanding young teachers Award, Henry Fok Education Foundation

2013       Wu Jieping-Paul Janssen Award in medicine & Pharmacy, Ministry of Health

2016       First prize for scientific and technological progress of JiangsuJiangsu Province

2012       Second prize for scientific and technological progress of JiangsuJiangsu Province

2007       Second prize for scientific and technological progress of JiangsuJiangsu Province

2014       Second prize for National Teaching Achievement Award, Ministry of Education

2009       Second prize for National Teaching Achievement Award, Ministry of Education


Books (selected):

  1. Chiral Drugs: Chemistry and Biological Action. Ed by Guo-Qiang Lin, Qi-Dong You and Jie-Fei Cheng, John Wiley & Sons, Inc. Hoboken, 2011

  2. Research and Evaluation of Chiral Drugs, Ed by Qi-Dong You and Guo-Qiang Lin, Chemical Industry Press. Beijing, 2011

  3. Medicinal Chemistry, 3rd edition, Ed by Qi-Dong You, Chemical Industry Press. Beijing, 2015

Papers and Articles (selected)

  1. Palladium(II)-Catalyzed C-H Bond Activation/C-C Coupling/Intramolecular Tsuji-Trost Reaction Cascade: Facile Access to 2H-Pyranonaphthoquinones. Bian, Jinlei; Qian, Xue; Wang, Nan; Mu, Tong; Li, Xiang; Sun, Haopeng; Zhang, Lianshan; You, Qidong; Zhang, Xiaojin. Org Lett. 2015, 17 (14):3410–3413

  2. Structure-Activity and Structure-Property Relationship and Exploratory in vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor. Zhengyu Jiang, Lili Xu, Mengchen Lu, Zhiyun Chen, Zhenwei Yuan, Xiaoli Xu, Xiaoke Guo,Xiaojin Zhang, Haopeng Sun, Qi-Dong You.J. Med. Chem.,201558 (16):6410–6421

  3. Discovery and Modification of in vivo active Nrf2 Activators with 1, 2, 4-oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. Xu, Lili; Zhu, Junfeng; Xu, Xiaoli; Zhu, Jie; Li, Li; Xi, Meiyang; Jiang, Zhengyu; Zhang, Mingye; Liu, Fang; Lu, Mengchen; Bao, Qichao; Zhang, Chao; Wei, Jinlian; Zhang, Xiaojin; You, Qi-Dong; Sun, Haopeng. J Med Chem.2015, 58 (14), pp 5419–5436

  4. Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: Introduction of an additional carboxyl group at the C-2 position of quinoline. Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.Eur J Med Chem. 2015, 105:145-155.

  5. Binding thermodynamics and kinetics guided optimization of potent Keap1-Nrf2 peptide inhibitors. Lu, M.-C.; Chen, Z.-Y.; Wang, Y.-L.; Jiang, Y.-L.; Yuan, Z.-W.; You, Q.-D. *; Jiang, Z.-Y. *RSC Advances 2015, 5:85983-85987

  6. Identification of Novel JMJD2A Inhibitor Scaffold Using Shape and Electrostatic Similarity Search Combined with Docking Method and MM-GBSA Approach. Feng, T. T.; Chen, W. L.; Li, D. D.; Lin, H. Z.; Liu, F.; Bao, Q. C.; Lei, Y. H.; Zhang, X. J.; Xu, X. L.; Guo, X. K.; You, Q. D.*; Sun, H. P.*RSC Advances,2015, 5:82936-82946.

  7. Discovery of NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with novel chemical scaffolds by shape-based virtual screening combined with cascade docking. Bian, J.; Qian, X.; Deng, B.; Xu, X.; Guo, X.; Wang, Y.;* Li, X.; Sun, H.; You, Q.;* Zhang, X.*RSC Advances, 2015, 5 (61), 49471-49479.

  8. Affinity-based fluorescence polarization assay for high-throughput screening of prolyl hydroxylase 2 inhibitors. Lei, Y.; Hu, T.; Wu, X.; Wu, Y.; Bao, Q.; Zhang, L.; Xia, H.; Sun, H.; You, Q.;* Zhang, X.* ACS Med. Chem. Lett., 2015, 6 (12), 1236−1240. (IF=3.120)

  9. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells. Xiao-Li Xu, Qi-chao Bao, Jian-Min Jia, Fang Liu, Xiao-Ke Guo, Ming-ye Zhang, Jin-lian Wei, Meng-chen Lu, Li-li Xu, Xiao-Jin Zhang, Qi-Dong You & Hao-Peng Sun.Scientific Reports2016, 6:19004

  10. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides. Lu, Meng-Chen, ,Yuan, Zhen-Wei,  Jiang, Yong-Lin, Chen, Zhi-Yun, You, Qi-Dong, Jiang, Zheng-Yu.Mol. BioSyst.,2016,12(4):1378-1387